Moderna Inc., US60770K1079

Moderna stock outlines oncology push at Jefferies conference

Published on 11/18/2026 at 13:54 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Moderna stock gained fresh attention at a Jefferies conference as management detailed its oncology strategy. Intismeran remains the central growth bet.

Moderna advances its oncology strategy

  • Management presented intismeran as a potential multi-billion-dollar opportunity in personalized cancer treatment.
  • Phase III melanoma data showed a hazard ratio of 0.58 in the intent-to-treat population and 0.51 among patients who received the blinded vaccine.
  • Moderna said it has dosed more than 2,000 patients and plans to expand its manufacturing capacity as clinical milestones advance.
Moderna Inc., US60770K1079, Illustration mit AI erstellt.

Moderna outlined its oncology strategy at the Jefferies Global Healthcare Conference on Wednesday, November 18, according to Investing.com. Management focused on intismeran, the company's personalized cancer vaccine candidate, and described the program as a potential multi-billion-dollar opportunity.

Moderna said recent Phase III data in adjuvant melanoma produced a hazard ratio of 0.58 in the intent-to-treat population. Among patients who received the blinded vaccine or control, the hazard ratio was 0.51. Management presented the results as the foundation for development in additional tumor types, including renal cell carcinoma, bladder cancer and lung cancer.

Clinical milestones shape the outlook

The company said nine randomized Phase II and Phase III studies are underway across the oncology program. An interim analysis in renal cell carcinoma is expected within the next 12 months, while final analysis in muscle-invasive bladder cancer is expected in 2027. A lung-cancer readout could come at the end of 2027 or in 2028, depending on the event-driven study design.

Moderna said more than 2,000 patients have received doses across the broader clinical program and that the final program is expected to enroll 5,000 patients. The company also highlighted a manufacturing success rate above 99% in its clinical experience and said its Marlborough, Massachusetts, facility is being prepared for commercial production.

Manufacturing and partnership remain key

Management said one manufacturing suite is currently operating and can support an initial melanoma launch, with as many as six additional suites planned as demand develops. At full build-out, the site is expected to supply tens of thousands of patients a year. Moderna and Merck share profits equally on the program, with both companies set to co-market intismeran in the United States and Merck responsible for commercialization outside the country.

Important execution steps remain ahead. Moderna still needs to advance regulatory filing, establish launch pricing and produce additional clinical data across the pipeline. Management said the company is commercially ready, but the timing and scale of any future oncology revenue will depend on regulatory progress, manufacturing expansion and the results of ongoing studies.

Moderna stock traded at 187.83 euros on Lang & Schwarz at 13:43 CET on Wednesday, November 18. The quote provides a current market reference as investors assess the oncology strategy and the company's transition beyond vaccines.

Moderna Inc. key facts

  • Company: Moderna Inc.
  • ISIN: US60770K1079
  • Ticker: MRNA
  • Primary exchange: Nasdaq
  • Lang & Schwarz quote: 187.83 euros at 13:43 CET on November 18, 2026

The broader US market context is available in current S&P 500 market reports.

More news and analyses on Moderna stock

Disclaimer...
en | US60770K1079 | MODERNA INC. | boerse | 70530975 | bgmi